Tag: date

Fiscal Year 2025 Earnings

ATLANTA, July 08, 2025 (GLOBE NEWSWIRE) -- Gray Media, Inc. (“Gray”) (NYSE: GTN) announced today the pricing of its previously announced private offering of $900 million aggregate principal amount of 9.625% senior secured second lien notes due 2032 (the “Notes”). This represents an increase of $150 million over the amount previously announced. The Notes were priced at 100% of par. The offering of the Notes is expected to close on July 18, 2025, subject to customary closing conditions.

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

As consumer interest in the best activated charcoal grows, NativePath introduces a clean-label, high-purity formula derived from coconut shells to support bloating, gas, and digestive detox.

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Semler Scientific, Inc. (NASDAQ: SMLR) resulting from allegations that Semler Scientific may have issued materially misleading business information to the investing public.

Transition Accompanies Strong Revenue Growth, Expanded Profitability, and Strengthened Balance Sheet

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent exposure. This study is being conducted in collaboration with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence, which is investigating pharmacological compounds, including Bucillamine, capable of mitigating nerve agent-induced brain injury.